Tina-quant® IgA CSF and Tina-quant® IgM CSF

For comprehensive cerebrospinal fluid (CSF) protein differentiation

  • The measurement of intrathecal IgA/M synthesis in combination with corresponding serum levels is used as an aid to the diagnosis of different neurological diseases. Increased CSF IgA and IgM concentrations may occur because of either increased permeability of the blood‑brain barrier or local/intrathecal production of IgA/IgM, or both.
  • An elevated albumin CSF/serum ratio is an indication of disorders of the blood‑brain barrier.
  • The results of the CSF/serum ratio for IgA/IgM and albumin, in conjunction with Reiber quotient scheme provide an aid in the diagnosis of functional blood‑brain barrier disorders and/or intrathecal IgA/IgM synthesis.
Tina-quant Immunoglobulin A CSF

Sample material CSF, serum, plasma
Measuring range CSF: 0.4 – 25 mg/L,
Serum, plasma: 0.1– 6 g/L
Precision (cobas c 501 module) Intraassay:
CSF: CV 1.0 – 3.1 %,
Serum, plasma: CV 1.2 – 3.1 %
Interassay:
CSF: CV 1.9 – 4.3 %
Serum, plasma: CV 1.3 – 4.2 %
Expected values CSF: 1– 3 mg/L. These values are for guidance only.
The only relevant values are the CSF/serum ratios
Serum, plasma: 0.7 – 4 g/L.
For values for children and juveniles please refer to the package insert


Tina-quant Immunoglobulin M CSF

Sample material
CSF, serum, plasma
Measuring range CSF: 0.1– 15 mg/L
Serum, plasma: 0.1– 5 g/L
Precision (cobas c 501 module) Intraassay:
CSF: CV 1.7 – 4.7 %
Serum, plasma: CV 1.5 – 2.0 %
Interassay:
CSF: CV 2.8 – 5.2 %
Serum, plasma: CV 1.7 – 2.3 %
Expected values CSF: 0.5 – 1.5 mg/L.
These values are for guidance only.
The only relevant values are the CSF/serum ratios
Serum, plasma: 0.4 – 2.3 g/L.
For values for children and juveniles please refer to the package insert
  • Full basic CSF diagnostic panel on a consolidated platform
  • Tina-quant IgA and IgM CSF offers excellent precision, onboard stability and calibration frequency
  • Possibility of using automated software-aided Reibergram analysis (third-party product tested with Roche analyzers)
  • Cost, labour and time savings through optimized workflow by offering ready-to-use reagents
  • Neurological diseases often present with non-specific clinical symptoms, and CSF analysis may provide valuable information to complement modern imaging techniques.
  • The combined results often form patterns typical of certain diseases, well supported by pathogen-specific diagnostic approaches.
  • CSF analysis is thus justified not only in acute conditions but even more so in chronic and autoimmune CNS diseases.

Kuhle J, Mehling M, Regeniter A, Moderne Liquordiagnostik Eine Übersicht, PRAXIS Schweiz Med Forum 2007;7:166–174